IBJNews

Lilly's profit drops 4 percent, but beats analysts' estimates

Back to TopCommentsE-mailPrintBookmark and Share

Price increases and sales gains helped Eli Lilly and Co. offset declining revenue from its former blockbuster Zyprexa in the fourth quarter, allowing the company to beat analysts' expectations and raise its 2013 profit forecast.

The Indianapolis-based drugmaker saw profit fall 4 percent, to $827 million, in the quarter, compared with the same period a year ago. That profit translated to earnings of 74 cents per share.

Excluding $204 million in charges for ending the development program of the pancreatic enzyme replacement drug liprotomase and further reducing employment, Lilly would have earned 85 cents per share in the quarter.

On that basis, analysts surveyed by Thomson Reuters were expecting earnings of 78 cents per share.

Lilly shares rose 3.6 percent by early afternoon, to $54.56 each.

Lilly’s fourth-quarter revenue declined 1 percent from a year ago, to just less than $6 billion. Analysts were expecting revenue of $5.8 billion.

“Lilly delivered solid financial results in the fourth quarter of 2012, as we successfully offset a large part of the revenue decline from the Zyprexa patent expiration with growth in other products such as Cymbalta, Forteo, Alimta, Effient and our animal health portfolio," Lilly CEO John Lechleiter said in a prepared statement.

Lilly boosted its 2013 profit forecast by 7 cents per share because Congress delayed the expiration of the research-and-development tax credit by one quarter. The company now expects to earn in the range of $4.10 to $4.25 per share this year. That would represent a gain of 12 percent to 16 percent over 2012.

For all of 2012, Lilly posted profit of $4.1 billion, or $3.66 per share, down 6 percent from 2011. Excluding special charges, Lilly earned $3.39 for the year,  exceeding the predictions of analysts by 6 cents.

Lilly’s 2012 revenue totaled $22.6 billion, a 7-percent decline from 2011. Analysts had been expecting full-year revenue of $22.4 billion.

Lilly’s U.S. and European patents on the antipsychotic drug Zypexa expired in the fall of 2011. That allowed cheaper generic versions of the drug to sap two-thirds of the drug’s $5 billion in annual sales.

That $3.3 billion hole in Lilly’s income statement has been mostly but not entirely filled by rising sales of other products. Sales of the antidepressant Cymbalta rose 20 percent last year to $5 billion. Sales of the osteoporosis drug Forteo and Elanco animal health products each rose 21 percent, to  $1.2 billion and $2 billion, respectively.

Lilly’s shares have risen 40 percent over the past 12 months, closing at $52.64 on Monday.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. It is nice and all that the developer grew up here and lives here, but do you think a company that builds and rehabs cottage-style homes has the chops to develop $150 Million of office, retail, and residential? I'm guessing they will quickly be over their skis and begging the city for even more help... This project should occur organically and be developed by those that can handle the size and scope of something like this as several other posters have mentioned.

  2. It amazes me how people with apparently zero knowledge of free markets or capitalism feel the need to read and post on a business journal website. Perhaps the Daily Worker would suit your interests better. It's definitely more sympathetic to your pro government theft views. It's too bad the Star is so awful as I'm sure you would find a much better home there.

  3. In other cities, expensive new construction projects are announced by real estate developers. In Carmel, they are announced by the local mayor. I am so, so glad I don't live in Carmel's taxbase--did you see that Carmel, a small Midwest suburb, has $500 million in debt?? That's unreal! The mayor thinks he's playing with Lego sets and Monopoly money here! Let these projects develop organically without government/taxpayer backing! Also, from a design standpoint, the whole town of Carmel looks comical. Grand, French-style buildings and promenades, sitting next to tire yards. Who do you guys think you are? Just my POV as a recent transplant to Indy.

  4. GeorgeP, you mention "necessities". Where in the announcement did it say anything about basic essentials like groceries? None of the plans and "vision" have basic essentials listed and nothing has been built. Traffic WILL be a nightmare. There is no east/west road capacity. GeorgeP, you also post on www.carmelchatter.com and your posts have repeatedly been proven wrong. You seem to have a fair amount of inside knowledge. Do you work on the third floor of Carmel City Hal?

  5. I don't know about the commuter buses...but it's a huge joke to see these IndyGo buses with just one or two passengers. Absolutely a disgusting waste of TAXPAYER money. Get some cojones and stop funding them. These (all of them) council members work for you. FIRE THEM!

ADVERTISEMENT